Market capitalization | $5.17m |
Enterprise Value | $-12.09m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 2.51 |
P/B ratio (TTM) P/B ratio | 0.26 |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-6.79m |
Free Cash Flow (TTM) Free Cash Flow | $-4.81m |
Cash position | $17.26m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
1 Analyst has issued a forecast Galmed Pharmaceuticals Ltd.:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | -0.09 -0.09 |
125%
125%
|
|
EBITDA | -6.70 -6.70 |
14%
14%
|
EBIT (Operating Income) EBIT | -6.79 -6.79 |
13%
13%
|
Net Profit | -6.32 -6.32 |
16%
16%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.
Head office | Israel |
CEO | Allen Baharaff |
Employees | 8 |
Founded | 2000 |
Website | galmedpharma.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.